SCHEMBL25297016

SCHEMBL25297016

COC(=O)c1ccc(S(=O)(=O)n2nc3c(c2C)C(=O)C(=O)c2ccccc2-3)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FBP1 P09467 1/20 0.47
▸ IDO1 P14902 2/20 0.44
▸ TDO2 P48775 1/20 0.44
▸ CTSG P08311 1/20 0.43
▸ CMA1 P23946 1/20 0.43
▸ GLA P06280 1/20 0.43
▸ CDC25B P30305 2/20 0.41
▸ PTPRC P08575 1/20 0.41
▸ PTPRF P10586 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ CDC25A P30304 1/20 0.40
▸ MAPT P10636 3/20 0.39
▸ KDM4A O75164 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HTT P42858 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29405316 1.00 FBP1 (0.47) FBP1IDO1TDO2CTSGCMA1
SCHEMBL25256191 0.84 KMT2A (0.46) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL29402693 0.84 KMT2A (0.46) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL29405655 0.83 NR1H2 (0.45) PTPRCKMT2AMEN1MAPTGAA
SCHEMBL25253327 0.83 NR1H2 (0.45) PTPRCKMT2AMEN1MAPTGAA
SCHEMBL25259052 0.83 KMT2A (0.42) PTPRCKMT2AMEN1MAPTALDH1A1
SCHEMBL29404553 0.83 KMT2A (0.42) PTPRCKMT2AMEN1MAPTALDH1A1
SCHEMBL25259709 0.81 TP53 (0.44) KMT2AMEN1MAPTGAAALDH1A1
SCHEMBL25257867 0.81 MEN1 (0.47) KMT2AMEN1MAPTALDH1A1SMN1; SMN2
SCHEMBL29405020 0.81 TP53 (0.44) KMT2AMEN1MAPTGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same LMITO THERAPEUTICS INC. (KR) 2026-03-10 — — US claimed
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME LMITO THERAPEUTICS INC. (KR) 2024-02-01 — — US claimed
EP-4212530-A1 IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME Lmito Therapeutics Inc. (KR) 2023-07-19 — — EP claimed
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same LMITO THERAPEUTICS INC. (KR) 2026-03-10 — — US disclosed
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME LMITO THERAPEUTICS INC. (KR) 2024-02-01 — — US disclosed
EP-4212530-A1 IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME Lmito Therapeutics Inc. (KR) 2023-07-19 — — EP disclosed
WO-2022039460-A1 IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME 주식회사 엘마이토테라퓨틱스 2022-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME NQO1, NFE2L2, KEAP1 FBP1 2484/4885IDO1 259/4885TDO2 392/4885
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same NQO1, CBR1, NFE2L2 FBP1 3030/4885IDO1 403/4885TDO2 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback